NCT01077635View on ClinicalTrials.gov

PENTA Fosamprenavir Study

CompletedOBSERVATIONAL

Enrollment

1

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)

HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY